At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 26 enrolled
Drug / intervention
LY2189265drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Dose Pharmacokinetic Study of LY2189265 in Subjects With Varying Degrees of Hepatic Impairment
In Brief
A Phase 1 clinical trial evaluating LY2189265 for Diabetes Mellitus, Type 2. Completed, enrolled 26 participants across 2 sites in 2 countries.
Detailed Summary
The primary purpose of this study is to help answer the following research questions, and not to provide treatment for any condition: * To evaluate how much of the study drug (LY2189265) is in the blood of participants with varying degrees of liver impairment compared to those with normal liver function. * To assess the safety of LY2189265 and any side effects that might be associated with it.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany, Hungary
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedDec 2010
Primary CompletionNov 2011
TodayJul 2026
First PostedDec 3, 2010
Enrollment StartNov 1, 2010
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.6 years ago
Interventions
LY2189265drug
Subcutaneous (SC) injection